You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Last Updated: January 22, 2021

DrugPatentWatch Database Preview


➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Carboplatin, and when can generic versions of Carboplatin launch?

Carboplatin is a drug marketed by Cipla Ltd, Eugia Pharma, Fresenius Kabi Usa, Hospira, Mylan Labs Ltd, Pliva, Sandoz, Watson Labs Teva, West-ward Pharms Int, Accord Hlthcare, Actavis Totowa, Akorn, Gland Pharma Ltd, Meitheal, Mylan Institutional, Novast Labs, Pharmachemie Bv, Pliva Lachema, Sandoz Inc, Sun Pharm, Teva Parenteral, and Teva Pharms Usa. and is included in thirty-three NDAs.

The generic ingredient in CARBOPLATIN is carboplatin. There are eighteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the carboplatin profile page.

US ANDA Litigation and Generic Entry Outlook for Carboplatin

A generic version of CARBOPLATIN was approved as carboplatin by HOSPIRA on October 14th, 2004.

  Start Trial

Drug patent expirations by year for CARBOPLATIN
Drug Prices for CARBOPLATIN

See drug prices for CARBOPLATIN

Recent Clinical Trials for CARBOPLATIN

Identify potential brand extensions & 505(b)(2) entrants

IpsenPhase 2
Stanford UniversityPhase 3
Joseph Sanchez FoundationPhase 2

See all CARBOPLATIN clinical trials

Pharmacology for CARBOPLATIN
Medical Subject Heading (MeSH) Categories for CARBOPLATIN
Paragraph IV (Patent) Challenges for CARBOPLATIN
Tradename Dosage Ingredient NDA Submissiondate

US Patents and Regulatory Information for CARBOPLATIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Labs Ltd CARBOPLATIN carboplatin INJECTABLE;INTRAVENOUS 091063-002 Nov 9, 2011 DISCN No No   Start Trial   Start Trial   Start Trial
Teva Pharms Usa CARBOPLATIN carboplatin INJECTABLE;INTRAVENOUS 077139-003 Sep 21, 2005 DISCN No No   Start Trial   Start Trial   Start Trial
Cipla Ltd CARBOPLATIN carboplatin INJECTABLE;INTRAVENOUS 077861-003 Jan 18, 2007 AP RX No No   Start Trial   Start Trial   Start Trial
Actavis Totowa CARBOPLATIN carboplatin INJECTABLE;INTRAVENOUS 078732-002 Feb 6, 2012 DISCN No No   Start Trial   Start Trial   Start Trial
Pliva Lachema CARBOPLATIN carboplatin INJECTABLE;INTRAVENOUS 078631-001 Dec 2, 2008 DISCN No No   Start Trial   Start Trial   Start Trial
Fresenius Kabi Usa CARBOPLATIN carboplatin INJECTABLE;INTRAVENOUS 077247-001 Oct 21, 2004 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.